rais expect profit contribut new
action rais forecast shionogi increas target price
return maintain
invest overview shionogi new flu drug xofluza lead
share voic sov japan amid brisk sale activ also launch
us novemb via roch xofluza approv us fda
around two month ahead schedul make readi year winter
flu season sale flu drug depend incid flu xofluza
attract strong interest abund inquiri physician drug
lead japanes sov show shionogi sale team make concert
effort behalf us demand flu drug rise last year flu
season prove deadli multipl fatal shionogi hiv franchis
gilead scienc
nonetheless secur certain degre market share compani
continu work maintain hiv franchis includ once-per-
month inject hiv treatment expect launch
risk low incid flu due warm winter weather factor
unforeseen advers event xofluza unknown caus
valuat base target price ep
previous forward price-to-earnings around unchang
roll forward base year
valuat metric
chang tp
number share mn
price month
price rel chart measur perform
topix close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price upsid rate outperform target price analyst fumiyoshi
profit tax
issuanc retir stock
net chang cash
number share mn
strongest
expect variou initi compani current undertak bear fruit
look hiv drug tivicay triumeq remain key driver think
mileston payment royalti inject hiv treatment cabotegravir also
come play point expect xofluza flu treatment choic
govern look stockpil countermeasur
pandem meanwhil anticip progress make domest oper cost-
effici includ reduc number mr
expect profit continu trend smoothli beyond think stronger
presenc shionogi hing establish independ oper us market
accordingli watch see whether pursu us
profit tax
cash equival
ethic drug sale japan
allevi opioid-induc adveres effect
allerg rhiniti caus house-dust mite allergen jpn
charl martineau pm univers toronto figur weekli nbrx market share hiv drug
weekli nbrx market share hiv drug sinc jan
figur roll posit
compani data financi result roll plan present materi
compani mention price
